Literature DB >> 10393857

Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease.

J Setsuda1, J Teruya-Feldstein, N L Harris, J A Ferry, L Sorbara, G Gupta, E S Jaffe, G Tosato.   

Abstract

T cell immunodeficiency plays an important role in the pathogenesis of posttransplant lymphoproliferative disease (PTLD) by permitting the unbridled expansion of Epstein-Barr virus (EBV)-infected B lymphocytes. However, factors other than T cell function may contribute to PTLD pathogenesis because PTLD infrequently develops even in the context of severe T cell immunodeficiency, and athymic mice that are T-cell-immunodeficient can reject EBV-immortalized cells. Here we report that PTLD tissues express significantly lower levels of IL-18, interferon-gamma (IFN-gamma), Mig, and RANTES compared to lymphoid tissues diagnosed with acute EBV-induced infectious mononucleosis, as assessed by semiquantitative RT-PCR analysis. Other cytokines and chemokines are expressed at similar levels. Immunohistochemistry confirmed that PTLD tissues contain less IL-18 and Mig protein than tissues with infectious mononucleosis. IL-18, primarily a monocyte product, promotes the secretion of IFN-gamma, which stimulates Mig and RANTES expression. Both IL-18 and Mig display antitumor activity in mice involving inhibition of angiogenesis. These results document greater expression of IL-18, IFN-gamma, Mig, and RANTES in lymphoid tissues with acute EBV-induced infectious mononucleosis compared to tissues with PTLD and raise the possibility that these mediators participate in critical host responses to EBV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393857      PMCID: PMC1866647          DOI: 10.1016/s0002-9440(10)65119-x

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  Interleukin-10 and Epstein-Barr virus-induced posttransplant lymphoproliferative disorder.

Authors:  S A Birkeland; K Bendtzen
Journal:  Transplantation       Date:  1996-05-15       Impact factor: 4.939

2.  Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines.

Authors:  P R Beatty; S M Krams; O M Martinez
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

3.  Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo.

Authors:  C Sgadari; J M Farber; A L Angiolillo; F Liao; J Teruya-Feldstein; P R Burd; L Yao; G Gupta; C Kanegane; G Tosato
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

4.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.

Authors:  T Kawano; J Cui; Y Koezuka; I Toura; Y Kaneko; K Motoki; H Ueno; R Nakagawa; H Sato; E Kondo; H Koseki; M Taniguchi
Journal:  Science       Date:  1997-11-28       Impact factor: 47.728

5.  IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB.

Authors:  D Robinson; K Shibuya; A Mui; F Zonin; E Murphy; T Sana; S B Hartley; S Menon; R Kastelein; F Bazan; A O'Garra
Journal:  Immunity       Date:  1997-10       Impact factor: 31.745

6.  Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein.

Authors:  S Ushio; M Namba; T Okura; K Hattori; Y Nukada; K Akita; F Tanabe; K Konishi; M Micallef; M Fujii; K Torigoe; T Tanimoto; S Fukuda; M Ikeda; H Okamura; M Kurimoto
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

Review 7.  Interleukin-10.

Authors:  K W Moore; A O'Garra; R de Waal Malefyt; P Vieira; T R Mosmann
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

8.  Suppression of Burkitt's lymphoma tumorigenicity in nude mice by co-inoculation of EBV-immortalized lymphoblastoid cells.

Authors:  J Wolf; A Draube; H Bohlen; A Jox; S Mücke; M Pawlita; P Möller; V Diehl
Journal:  Int J Cancer       Date:  1995-02-08       Impact factor: 7.396

9.  Management of lymphoproliferative disorders after cardiac transplantation.

Authors:  J M Chen; M L Barr; A Chadburn; G Frizzera; F A Schenkel; R R Sciacca; D S Reison; L J Addonizio; E A Rose; D M Knowles
Journal:  Ann Thorac Surg       Date:  1993-09       Impact factor: 4.330

10.  Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin.

Authors:  D J Weissmann; J A Ferry; N L Harris; D N Louis; F Delmonico; I Spiro
Journal:  Am J Clin Pathol       Date:  1995-06       Impact factor: 2.493

View more
  11 in total

Review 1.  Molecular pathways in virus-induced cytokine production.

Authors:  T H Mogensen; S R Paludan
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

2.  Lymphoid tissues from patients with infectious mononucleosis lack monoclonal B and T cells.

Authors:  Julie A Plumbley; Hongxin Fan; Phyllis A Eagan; Aamir Ehsan; Bertram Schnitzer; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

Review 3.  Epstein-Barr virus and systemic lupus erythematosus.

Authors:  Anette Holck Draborg; Karen Duus; Gunnar Houen
Journal:  Clin Dev Immunol       Date:  2012-07-03

4.  Interleukin-4 and interferon- γ levels in Epstein-Barr virus-associated infectious mononucleosis and nasopharyngeal carcinoma.

Authors:  Dyah R Budiani; Sofia M Haryana; Wihaskoro Sosroseno
Journal:  J Res Med Sci       Date:  2011-01       Impact factor: 1.852

5.  Hydroa vacciniforme-like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites.

Authors:  Jeffrey I Cohen; Irini Manoli; Kennichi Dowdell; Tammy A Krogmann; Deborah Tamura; Pierce Radecki; Wei Bu; Siu-Ping Turk; Kelly Liepshutz; Ronald L Hornung; Hiva Fassihi; Robert P Sarkany; Lori L Bonnycastle; Peter S Chines; Amy J Swift; Timothy G Myers; Melissa A Levoska; John J DiGiovanna; Francis S Collins; Kenneth H Kraemer; Stefania Pittaluga; Elaine S Jaffe
Journal:  Blood       Date:  2019-05-07       Impact factor: 25.476

6.  Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients.

Authors:  Anette Holck Draborg; Søren Jacobsen; Marie Westergaard; Shila Mortensen; Janni Lisander Larsen; Gunnar Houen; Karen Duus
Journal:  Lupus Sci Med       Date:  2014-04-01

7.  Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases.

Authors:  Rachel J Abbott; Annette Pachnio; Isabela Pedroza-Pacheco; Alison M Leese; Jusnara Begum; Heather M Long; Debbie Croom-Carter; Andrea Stacey; Paul A H Moss; Andrew D Hislop; Persephone Borrow; Alan B Rickinson; Andrew I Bell
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

8.  Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-κB and Btk.

Authors:  Joo Hyun Kim; Won Seog Kim; Jung Yong Hong; Kung Ju Ryu; Seok Jin Kim; Chaehwa Park
Journal:  Oncotarget       Date:  2017-01-17

9.  Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV+ Human Primary B-cells.

Authors:  Laura E Martínez; Tracy R Daniels-Wells; Yu Guo; Larry I Magpantay; Pierre V Candelaria; Manuel L Penichet; Otoniel Martínez-Maza; Marta Epeldegui
Journal:  Mol Cancer Ther       Date:  2021-06-22       Impact factor: 6.261

10.  Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients.

Authors:  Anette Holck Draborg; Noreen Sandhu; Nanna Larsen; Janni Lisander Larsen; Søren Jacobsen; Gunnar Houen
Journal:  J Immunol Res       Date:  2016-03-27       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.